A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00219050
- Lead Sponsor
- Novartis
- Brief Summary
To compare the safety and efficacy of an aliskiren-based regimen to a lisinopril-based regimen in the treatment of severe hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Evaluate safety through adverse events and laboratory abnormalities after 8 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 8 weeks Change from baseline in systolic blood pressure after 8 weeks Change from baseline in standing systolic blood and diastolic pressure after 8 weeks Diastolic blood pressure is less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks
Trial Locations
- Locations (2)
Novartis Pharmaceuticals
🇨🇭Basel, Switzerland
Investigative Site
🇪🇸Madrid, Spain